A review in the journal Expert Opinion on Biological Therapy (http://dx.doi.org/10.1517/14712598.2016.1093110) has highlighted the existence of almost 20 clinical trials, either completed or on-going, in… Read More »University of California review highlights increasing activity in clinical trial stem cell research
Research, led by scientists at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, has shown a mechanistic link between fragments of mitochondrial DNA (mtDNA)… Read More »Mitochondrial DNA (mtDNA) provides novel mechanistic link to release of pro-inflammatory cytokines and AMD pathogenesis.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 2nd, 2015 edition of EURETINA’s web-based digital magazine,… Read More »October 2nd, 2015: “EURETINA-Brief”© Issue No. 118
Research from Tufts University, Boston, has indicated that evidence remains inconclusive in regards to whether or not zinc intake from foods and supplements is beneficial… Read More »The effects of zinc on the prevention and treatment of AMD are far from conclusive, according to a systematic review
Santhera Pharmaceuticals (SIX: SANN), a Swiss based company focused on the treatment of mitochondrial and neuromuscular disease, has announced the receipt of marketing authorization for… Read More »Santhera Pharmaceuticals (Switzerland) announces first approval by the European Commission for a Leber’s Hereditary Optic Neuropathy (LHON) treatment
Clinical research performed by the Department of Ophthalmology, University of Bonn, Germany, has shown that microperimetry assessment in patients suffering macular telangiectasia type 2 (MacTel2)… Read More »Microperimetry may provide a more sensitive tool in measuring progression of macular telangiectasia type 2
Research, led by scientists at the Department of Ophthalmology, Tufts University School of Medicine, Boston, has shown that complement Factor H, virally delivered to the… Read More »Gene therapy approach to treating AMD with virally delivered complement Factor H shows potential in animal models.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 16th, 2015 edition of EURETINA’s web-based digital magazine,… Read More »September 16th, 2015: “EURETINA-Brief”© Issue No. 117
Inherited retinal disorders (IRDs) are estimated to affect millions of individuals on a global scale, in many instances leading to significantly reduced vision or blindness.… Read More »Converting rods into cones in a model of retinitis pigmentosa (RP) rescues retinal degeneration.
StemCells Inc., (NASDAQ: STEM), based in Newark, California, has announced the dosing of a first patient with purified human neural stem cells directed at the… Read More »StemCells Inc., transplants first patient in Phase II clinical trial for dry age-related macular degeneration